Form 4: Alkermes Executive Sells Shares Under 10b5-1 Trading Plan

Craig C. Hopkinson, EVP R&D and Chief Medical Officer at Alkermes plc, sold 9,221 ordinary shares at $31.50 per share under a pre-arranged 10b5-1 trading plan.

Summary

• Craig C. Hopkinson, an executive at Alkermes plc, sold 9,221 ordinary shares of the company.
• The sale occurred on December 5, 2024, at a price of $31.50 per share.
• The transaction was executed under a Rule 10b5-1 trading plan adopted by Mr. Hopkinson on December 14, 2023.
• Following the sale, Mr. Hopkinson directly owns 59,730 ordinary shares of Alkermes.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an executive's share sale under a pre-arranged plan. It does not indicate any positive or negative sentiment about the company's performance.

Industry Context

This is a routine filing related to insider trading activity. It is common for executives to use 10b5-1 plans to sell shares to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies to manage their personal finances while avoiding potential insider trading issues.
• Similar filings are regularly made by executives at comparable pharmaceutical and biotech companies such as Biogen, Vertex Pharmaceuticals, and Regeneron Pharmaceuticals.

Stakeholder Impact

• The share sale by an executive may have a minor impact on shareholder sentiment, but it is unlikely to significantly affect the company's stock price due to the pre-planned nature of the transaction.

Key Dates

Keywords

Alkermes, insider trading, Form 4, share sale, Rule 10b5-1, executive, Hopkinson, ALKS